{"url_path":"/sec/nrix/8-k/2026-07-09/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000038-index.html","accession_number":"0001549595-26-000038","cik":"0001549595","ticker":"NRIX","issuer_name":"Nurix Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000038-index.html","primary_entity_key":"0001549595","primary_entity_name":"Nurix Therapeutics, Inc."},"word_count":86,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d)Exhibits\n\nExhibit No.Exhibit Title or Description\n\n99.1\n[Press Release dated July 9, 2026](nrix-20260709xexx991.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\n2\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nNURIX THERAPEUTICS, INC.\n\nDate: July 9, 2026\nBy:/s/ Arthur T. Sands\n\nArthur T. Sands, M.D., Ph.D.\n\nPresident and Chief Executive Officer\n\n3"}